Specialty Pharmacy

FDA breakthrough designation is based on data for nivolumab plus ipilimumab in a study evaluating the immuno-oncology combination in patients with advanced hepatocellular carcinoma previously treated with sorafenib.

Oligodendrocyte progenitor cells were often ignored by scientists studying multiple sclerosis; however, new research shows that they are critical in its production.

Top news of the day from across the health care landscape.

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss how specialty pharmacists can show their value during the NASP Annual Meeting in Washington, DC.

Jesse C. Dresser, Esq explains a recent piece of PBM legislation from North Dakota and its implications for specialty pharmacy at the NASP Annual Meeting in Washington, DC.

A supplemental New Drug Application (sNDA) was submitted to the FDA for ibrutinib (Imbruvica, AbbVie) in combination with rituximab for the first-line treatment of younger patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

With this approval, luspatercept-aamt (Reblozyl, Celgene) is the first FDA-approved erythroid maturation agent for anemia in beta thalassemia

Study is the first to identify the presence of anti-citrullinated protein autoantibodies in human tear fluid as well as discover the new eye drop treatment.

A phase 3 study evaluated ixazomib (Ninlaro, Takeda) in the first-line maintenance therapy setting for patients with multiple myeloma who have not undergone autologous stem cell transplant.

The discovery is the first time a new subtype of HIV-1 has been identified since 2000.

Top news of the day from across the health care landscape.

Because cystic fibrosis transmembrane conductance regulator modulator therapies are new, researchers sought to understand patient adherence as well as potential challenges.

Top news of the week from Specialty Pharmacy Times.

Rituximab-abbs (Truxima, Teva and Celltrion), has been launched in the United States with a full oncology label for non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Top news of the day from across the health care landscape.

The ADMIRAL trial found that gilteritinib is a significant addition to the treatments available for patients with FLT3 mutation-positive relapsed or refractory acute myeloid leukemia.

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss why data standardization is important in specialty pharmacy and how technology plays into it during the NASP Annual Meeting in Washington, DC.

Top news of the day from across the health care landscape.

Study shows a significantly greater proportion of patients with Crohn disease who were administered ustekinumab every 8 weeks achieved a histologic response.

Top news of the day from across the health care landscape.

Pegfilgrastim-bmez (Ziextenzo, Sandoz), a biosimilar to pegfilgrastim (Neulasta), is indicated to decrease the incidence of febrile neutropenia, a serious adverse effect of chemotherapy.

Study seeks to determine the prevalence and clinical significance of red blood cell-bound immunoglobulin G as detected by flow cytometry in polytransfused patients with thalassemia.

Jesse C. Dresser, Esq explains how specialty pharmacists can educate and inform legislators on PBM reform at the NASP Annual Meeting in Washington, DC.

Dicyclomine Hydrochloride Injectable is the generic version of Bentyl from Allergan and is used to treat functional bowel or irritable bowel syndrome.

Omeprazole magnesium, amoxicillin, and rifabutin (Talicia, RedHill Biopharma) is indicated for the treatment of Helicobacter pylori (H. pylori) infection in adults.

Top news of the day from across the health care landscape.

Advancements in the understanding of asthma pathophysiology has led to the discovery of defined asthma phenotypes and targeted interventions involving novel biologic therapies.

Three complement genes identified in a new study may serve as markers for monitoring and predicting the progression and severity of multiple sclerosis.

Texas oncologist Stephen Hahn, MD, is expected to receive the Trump administration’s nomination for the role of FDA Commissioner, a move that had been anticipated by federal insiders.

Top news of the week from Specialty Pharmacy Times.